News archive
Showing 705 results
July 2014
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University… -
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
June 2014
-
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin… -
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
May 2014
-
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
Pivotal data in ALK+ NSCLC for Zykadia™; recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designationFirst presentation of pivotal data from Phase III trial… -
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2)Phase III data show patients on… -
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
March 2014
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or… -
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age… -
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives